Recent News

  • profile

    24-Feb-2017

    The theme is “research” and the slogan is “with research possibilities are limitless”.    www.rarediseaseday.org
  • profile

    18-Feb-2017

    Withdrawal of Marketing Authorization Application for Aceneuramic Acid Prolonged Release (Ace-ER) in the European Union.
  • profile

    16-Mar-2017

    The theme is “research” and the slogan is “with research possibilities are limitless” Read more at: http://www.rarediseaseday.org/page/news/2017-theme-research Ultragenyx Announces Withdrawal of Marketing Authorization Application for Aceneuramic Acid Prolonged Release (Ace-ER) in the European Union. Read more at: http://files.shareholder.com/downloads/AMDA-2CDCD3/
    Read More...
  • profile

    08-Mar-2017

    Policy shame: sick, rare and ignored http://http://www.thehindu.com/opinion/op-ed/the-draft-national-health-policy-ignores-rare-diseases/article8318356.ece/
  • profile

    17-Jul-2015

    New Method for Production of Muscle Cells from Stem cells that may have promise for a treatment for GNE-myopathy and other inherited diseases. http://musculardystrophynews.com/2015/07/28/promising-therapy-muscular-dystrophy-based-adult-stem-cells/
  • profile

    21-Mar-2017

    Release (Ace-ER) in the European Union. For details see http://files.shareholder.com/downloads/AMDA-2CDCD3/2736159177x0x917129/E3CA6B05-3FAA-4E29-BA0D-83802604165B/RARE_News_2016_11_11_General_Releases.pdf
  • profile

    28-May-2015

    Ultragenyx Announces First Patient Enrolled in Global Phase 3 Study of Aceneuramic Acid (Sialic Acid) Extended Release in GNE Myopathy http://www.ultragenyx.com/ht/a/GetDocumentAction/i/45418
  • profile

    04-Apr-2015

    "A Couple Participating in The Boston Marathon is Helping to Raise Awareness for Gne-Myopathy" A couple (Mike and Christine) runners who will be participating in the Boston Marathon has graciously "adopted" me as partner/patient. One of my goals is to globally bring an understanding, and increase the awareness of Gne-Myopathy. We are very fortunate, in addition to recent att
    Read More...
  • profile

    23-Mar-2015

    "Road To The Cure" - Rare Disease Day Symposium at the Sanford/Burnham Research Institute" I was very fortunate to be able to attend a Rare Disease Day Symposium at the Sanford Burnham Research Institute in La Jolla, California. This campus is located in a coastal area, and the views were quite stunning. I wish more of us could have been able to attend. This symposium was enti
    Read More...
  • profile

    28-Feb-2015

    Rare Disease Day Some of the online events: http://www.rarediseaseday.org/event/india/149  http://www.sanfordburnham.org/research/programs/genetics/symposium/Pages/2015.aspx?ItemId=1
  • profile

    19-Feb-2015

    An Open Label Phase 2 Study of DEX-M74 in Subjects With GNE Myopathy The National Institutes of Health in Bethedsa, Maryland. U.S.A. has started recruiting patients with gne-myopathy for a clinical trial using ManNac. They plan to treat 12 patients in the clinical trial. Here is the link with very detailed information. If you have any questions, please feel free to send us an emailhttps://cl
    Read More...
  • profile

    Synthetic stem cells:

    One of the major problem of stem cell treatment is high potential for getting cancer due to the property of these cells to grow and becomecancerous. A new technique that allows synthetic stem cells to be created, has been successful in treating damaged heart muscles. Read more at: http://www.christian.org.uk/news/ethical-stem-cell-technique-repairs-heart-without-cancer-risk/
  • profile

    Gene corrected stem cells:

    Autologous stem cells, that is, cells taken from the same patients where it is supposed to be used, can be useful in treatment of patients with rare genetic disorders. These cells are generally non toxic and have fewer side effects. Unfortunately the cells would have the mutant gene as these have been obtained from patients. If the genetic defect can be repaired, then the corrected stem cells can
    Read More...
  • profile

    Analysis of GNE mutations

    A research group at National Institutes of Health, USA have analysed 154 reported and novel gene variants associated with GNE myopathy. The authors have also predicted likely effect of those mutations on the function of GNE protein. Based on the frequency of these variations in the population they have estimated that the number of patients can be much higher than what is thought to be current numb
    Read More...
  • profile

    Sialyllactose therapy for GNE myopathy

    Scientists from the Institute of neuroscience, Japan have shown that sialyllactose supplementation can alleviate the symptoms of GNE myopathy in a mouse model in a dose dependent manner. This derivative was found to be more effective than free sialic acid. In these experiments the supplementation was given after the onset of the disease, mimicking human conditions. Sialyllactose is a natural deriv
    Read More...